Literature DB >> 8465799

How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease.

M Packer1.   

Abstract

During the last 50 years, physicians have developed three distinct conceptual models of heart failure that have provided a rational basis for the treatment of the disease. In the 1940s through the 1960s, physicians regarded heart failure principally as an edematous disorder and formulated a cardiorenal model of the disease in an attempt to explain the sodium retention of these patients. This model led to the widespread use of digitalis and diuretics. In the 1970s and 1980s, physicians viewed heart failure principally as a hemodynamic disorder and formulated a cardiocirculatory model of the disease in an attempt to explain patients' symptoms and disability. This model led to the widespread use of peripheral vasodilators and the development of novel positive inotropic agents. Now, in the 1990s, physicians are beginning to think about heart failure as a neurohormonal disorder in an attempt to explain the progression of the disease and its poor long-term survival. This new conceptual framework has led to the widespread use of converting-enzyme inhibitors and the development of beta blockers for the treatment of heart failure. Which conceptual model most accurately describes the syndrome of heart failure and leads physicians to utilize the most effective treatment? This paper critically reviews the available evidence supporting and refuting the validity of all three models of heart failure. We conclude that, to varying degrees, all three approaches provide useful, but incomplete, insights into this physiologically complex and therapeutically challenging disease.

Entities:  

Mesh:

Year:  1993        PMID: 8465799     DOI: 10.1016/0002-9149(93)90081-m

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  The treatment of heart failure in the 21st century: is the glass half empty or half full?

Authors:  Biykem Bozkurt; Douglas L Mann
Journal:  Methodist Debakey Cardiovasc J       Date:  2013 Jan-Mar

Review 2.  Pharmacotherapy of congestive heart failure. Currently used and experimental drugs.

Authors:  P A van Zwieten
Journal:  Pharm World Sci       Date:  1994-12-02

Review 3.  Heart failure following anterior myocardial infarction: an indication for ventricular restoration, a surgical method to reverse post-infarction remodeling.

Authors:  Alfred W H Stanley; Constantine L Athanasuleas; Gerald D Buckberg
Journal:  Heart Fail Rev       Date:  2004-10       Impact factor: 4.214

4.  The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects.

Authors:  H Knauf; M A Bailey; G Hasenfuss; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  2006-09-09       Impact factor: 2.953

5.  Neurohormonal Therapy for Congestive Heart Failure.

Authors:  Allison M Pritchett; Douglas L Mann
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-12

Review 6.  Adrenal G Protein-Coupled Receptors and the Failing Heart: A Long-distance, Yet Intimate Affair.

Authors:  Jordana I Borges; Krysten E Ferraino; Natalie Cora; Deepika Nagliya; Malka S Suster; Alexandra M Carbone; Anastasios Lymperopoulos
Journal:  J Cardiovasc Pharmacol       Date:  2022-09-01       Impact factor: 3.271

Review 7.  Cardioselectivity of calcium antagonists.

Authors:  T Godfraind
Journal:  Cardiovasc Drugs Ther       Date:  1994-05       Impact factor: 3.727

Review 8.  Mechanisms and Models in Heart Failure: A Translational Approach.

Authors:  Douglas L Mann; G Michael Felker
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

9.  Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure.

Authors:  Milton Packer
Journal:  J Am Heart Assoc       Date:  2020-08-01       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.